Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NXGL NASDAQ:NXL NASDAQ:OSRH NASDAQ:QNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNXGLNexGel$2.57+14.2%$2.42$2.10▼$5.10$19.67M0.5747,268 shs113,216 shsNXLNexalin Technology$0.99-1.1%$1.11$0.59▼$4.49$16.99M3.69127,233 shs21,833 shsOSRHOSR$0.64-6.7%$1.25$0.62▼$13.40$12.38M1.51.34 million shs400,311 shsQNRXQuoin Pharmaceuticals$6.66-0.6%$8.69$5.01▼$54.95$4.01M1.444,032 shs3,184 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNXGLNexGel0.00%+8.90%-1.15%-3.38%-18.15%NXLNexalin Technology0.00%-14.75%+3.33%-44.75%-14.01%OSRHOSR0.00%-34.46%-52.42%-54.45%+64,229,900.00%QNRXQuoin Pharmaceuticals0.00%-19.86%-26.65%+9.18%-68.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNXGLNexGel0.5383 of 5 stars0.04.00.00.00.02.50.0NXLNexalin Technology2.8939 of 5 stars3.55.00.00.02.51.70.0OSRHOSRN/AN/AN/AN/AN/AN/AN/AN/AQNRXQuoin Pharmaceuticals1.6787 of 5 stars0.05.00.00.02.40.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNXGLNexGel 0.00N/AN/AN/ANXLNexalin Technology 3.00Buy$5.00405.61% UpsideOSRHOSR 0.00N/AN/AN/AQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNXGLNexGel$8.69M2.26N/AN/A$0.90 per share2.86NXLNexalin Technology$170K99.94N/AN/A$0.28 per share3.53OSRHOSRN/AN/AN/AN/A($3.87) per shareN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/A$35.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNXGLNexGel-$3.28M-$0.45N/A∞N/A-30.80%-54.95%-27.84%8/18/2025 (Estimated)NXLNexalin Technology-$7.61M-$0.83N/A∞N/A-6,529.77%-277.92%-245.37%8/14/2025 (Estimated)OSRHOSR-$2.41MN/A0.00∞N/AN/A-36.89%-19.14%N/AQNRXQuoin Pharmaceuticals-$8.96M-$48.81N/AN/AN/AN/A-148.97%-77.23%8/7/2025 (Estimated)Latest QNRX, NXL, OSRH, and NXGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025NXGLNexGel-$0.07N/AN/AN/A$3.08 millionN/A8/7/2025Q2 2025QNRXQuoin Pharmaceuticals-$6.83N/AN/AN/AN/AN/A5/20/2025Q1 2025OSRHOSRN/A-$1.04N/A-$1.04N/A$0.76 million5/13/2025Q1 2025NXGLNexGel-$0.10-$0.09+$0.01-$0.09$2.73 million$2.81 million5/13/2025Q1 2025NXLNexalin Technology-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 million5/13/2025Q1 2025QNRXQuoin Pharmaceuticals-$3.85-$6.50-$2.65-$6.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNXGLNexGelN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNXGLNexGel0.151.881.15NXLNexalin TechnologyN/A4.564.25OSRHOSRN/A0.250.20QNRXQuoin PharmaceuticalsN/A2.572.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNXGLNexGel2.21%NXLNexalin Technology0.65%OSRHOSR55.30%QNRXQuoin Pharmaceuticals8.63%Insider OwnershipCompanyInsider OwnershipNXGLNexGel20.55%NXLNexalin Technology25.26%OSRHOSR33.67%QNRXQuoin Pharmaceuticals13.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNXGLNexGel107.65 million6.08 millionNot OptionableNXLNexalin Technology317.18 million12.84 millionNot OptionableOSRHOSRN/A19.28 million12.79 millionN/AQNRXQuoin Pharmaceuticals4590,000509,000Not OptionableQNRX, NXL, OSRH, and NXGL HeadlinesRecent News About These CompaniesQuoin Pharmaceuticals (QNRX) to Release Quarterly Earnings on ThursdayAugust 2 at 2:52 AM | americanbankingnews.comQuoin Pharmaceuticals stock rises after positive clinical updatesJuly 31 at 3:14 AM | investing.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Product Portfolio UpdateJuly 29, 2025 | finanznachrichten.deQuoin Pharmaceuticals Provides Product Portfolio UpdateJuly 29, 2025 | globenewswire.comQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases - MorningstarJune 27, 2025 | morningstar.comMQuoin Pharmaceuticals Releases New Episode of NETHERTON NOW Featuring Expert Insights on Netherton Syndrome - NasdaqJune 27, 2025 | nasdaq.comQNRX - Quoin Pharmaceuticals Ltd ADR Executives - MorningstarJune 26, 2025 | morningstar.comMQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin DiseasesJune 26, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome - Yahoo FinanceJune 25, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton SyndromeJune 24, 2025 | tmcnet.comQuoin Pharmaceuticals, Ltd. (QNRX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comQNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand FurtherMay 29, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical StudyMay 22, 2025 | manilatimes.netMQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton SyndromeMay 20, 2025 | globenewswire.comQuoin reports progress in pediatric skin disorder studyMay 15, 2025 | investing.comQuoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome StudyMay 14, 2025 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial ResultsMay 14, 2025 | manilatimes.netMA Peek at Quoin Pharmaceuticals's Future EarningsMay 12, 2025 | benzinga.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleMay 1, 2025 | finanznachrichten.deQuoin Pharmaceuticals regains Nasdaq compliance with bid priceMay 1, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNRX, NXL, OSRH, and NXGL Company DescriptionsNexGel NASDAQ:NXGL$2.57 +0.32 (+14.22%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.60 +0.03 (+1.32%) As of 08/1/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.Nexalin Technology NASDAQ:NXL$0.99 -0.01 (-1.11%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.99 0.00 (-0.29%) As of 08/1/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.OSR NASDAQ:OSRH$0.64 -0.05 (-6.67%) As of 08/1/2025 03:59 PM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.Quoin Pharmaceuticals NASDAQ:QNRX$6.66 -0.04 (-0.60%) Closing price 08/1/2025 03:56 PM EasternExtended Trading$6.66 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
